Neurocrine Biosciences reported $28.3M in Stock for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Stock Change
Acadia Pharmaceuticals ACAD:US $ 10.79M 0.48M
Adamas Pharmaceuticals ADMS:US 7.79M 252K
Alexion Pharmaceuticals ALXN:US $ 803.9M 28.2M
ALKERMES ALKS:US $ 136.08M 1.9M
Alnylam Pharmaceuticals ALNY:US $ 84.36M 6.68M
Amgen AMGN:US $ 4115M 98M
Biogen BIIB:US $ 1254.8M 83M
Biomarin Pharmaceutical BMRN:US $ 710.98M 2.95M
Dynavax Technologies DVAX:US $ 86.45M 17.6M
Exelixis EXEL:US $ 24.98M 0.22M
Gilead Sciences GILD:US $ 2988M 8M
Halozyme Therapeutics HALO:US $ 58.55M 0.21M
IONIS PHARMACEUT IONS:US $ 24.1M 1.9M
Nektar Therapeutics NKTR:US $ 14.62M 2.19M
Neurocrine Biosciences NBIX:US $ 28.3M 1.8M
Regeneron Pharmaceuticals REGN:US $ 1983.9M 318.6M
Teva Pharmaceutical TEVA:IT 4.36B 44M
Ultragenyx Pharmaceutical RARE:US $ 15.08M 2.62M
Vertex Pharmaceuticals VRTX:US $ 321.62M 22.76M
YTE INCY:US $ 16.68M 0.02M
Zogenix ZGNX:US $ 2.92M 0.6M